Genfit S.A.

OTCPK:GNFT.Y Aktierapport

Börsvärde: US$541.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Genfit Förvaltning

Förvaltning kriterier kontrolleras 3/4

Genfit VD är M. Prigent, utsedd i Sep 2019, har en mandatperiod på 6.5 år. totala årliga ersättningen är € 681.95K, bestående av 59.5% lön 40.5% bonusar, inklusive företagsaktier och optioner. äger direkt 0.062% av företagets aktier, värda $ 333.78K. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 4 år respektive 8.8 år.

Viktig information

M. Prigent

Verkställande direktör

€681.9k

Total ersättning

VD-lön i procent59.47%
Anställning som VD6.5yrs
Ägande av VD0.06%
Ledningens genomsnittliga anställningstid4yrs
Styrelsens genomsnittliga mandatperiod8.8yrs

Senaste uppdateringar av ledningen

Recent updates

Seeking Alpha • Nov 21

Genfit Balances Ipsen Partnership With High-Risk Pipeline Ambitions

Summary Genfit's Iqirvo received FDA approval in June 2024 for treating primary biliary cholangitis. Gilead's Livdelzi has shown superior efficacy in reducing alkaline phosphatase levels in PBC patients. Genfit licensed Iqirvo's global rights to Ipsen in 2021, securing milestone payments and royalties. Genfit's pipeline includes VS-01 for acute-on-chronic liver failure and GNS561 for cholangiocarcinoma. Given Iqirvo's competitive challenges and speculative pipeline, Genfit's long-term prospects remain uncertain. Read the full article on Seeking Alpha
Seeking Alpha • Sep 28

Genfit GAAP EPS of -€0.21, revenue of €12.19M

Genfit press release (NASDAQ:GNFT): 1H GAAP EPS of -€0.21. Revenue of €12.19M (+255.4% Y/Y). Shares +3.27%.
Seeking Alpha • Sep 19

Genfit to acquire Swiss-based Versantis focused on liver diseases

Genfit (NASDAQ:GNFT) on Monday announced that it has signed an exclusivity agreement to acquire a private Swiss-based clinical stage biotechnology firm- Versantis - at an initial consideration of CHF 40M. Headquartered in Zurich, Switzerland, Versantis is focused on drug and diagnostic product development for the acute-on-chronic liver failure (ACLF) and other unmet medical needs in liver diseases. Its main asset, VS-01, is claimed as first-in-class innovative liposomal-based therapeutic product candidate currently in clinical development for the timely recovery of ACLF and UCD. If approved, it would be the first drug to use the intraperitoneal route to simultaneously support the liver, kidney and brain, the organs that most often fail in cirrhotic patients. Consideration: This acquisition deal comprises of initial CHF 40M due at closing and consideration of up to CHF 65M upon positive Phase 2 results for VS-01 and VS-02 and regulatory approval of VS-01. Also, Versantis is eligible to receive 1/3 of the net proceeds resulting from the potential sale of the pediatric review voucher of VS-01.  Pascal Prigent, Chief Executive Officer of GENFIT, commented: “Versantis has an exciting portfolio that is complementary to GENFIT’s. We are also thrilled to welcome a talented team that has developed a strong scientific expertise in ACLF. We believe that significant synergies exist and that this acquisition will accelerate the development of several promising drug candidates in areas of high unmet needs.”
Seeking Alpha • Sep 07

Genfit S.A.: A 'Sum Of The Parts' Story

Summary Today, we put France-based biotech concern Genfit S.A. back in the spotlight for the first time in a year and a half. The company has a lot of moving parts and little analyst coverage but seems to be advancing its pipeline forward. An investment analysis follows in the paragraphs below. How can you govern a country which has 246 varieties of cheese?"― Charles de Gaulle We last posted a piece on small biotech outfit Genfit S.A. (GNFT) in March of 2021. We concluded saying the company has some interesting attributes, but it was probably too early to take a stake in its pending further development. The stock trades almost exactly where it did 18 months ago. No one else on Seeking Alpha has covered the company since then. Therefore, we will circle back on this name today. Seeking Alpha Company Overview: This France-based clinical stage biotech concern is focused on developing treatments primarily to treat disease of the liver and from gastroenterology. The shares currently trade just above four bucks a share and sports a market capitalization just north of $200 million. April Company Presentation Genfit is developing several compounds within its pipeline. Elafibranor, a dual agonist of PPARα and PPARδ, has shown encouraging results in mid-stage studies evaluating it to treat Primary Biliary Cholangitis or PBC. Elafibranor has Breakthrough Therapy and Orphan Drug status for PBC it should be noted. In late 2021, the company announced that it entered into an arrangement with Ipsen that will give that drug maker exclusive worldwide license to develop, manufacture and commercialize Elafibranor. April Company Presentation Genfit received a €120 million upfront payment for this license agreement and also can garner milestone payments up to €360 million (roughly 50% of this is for developmental milestones), plus tiered double-digit royalties of up to 20% on any commercialized sales. €80 million of the upfront payment was recognized as revenue in 2021, and €40 million was booked as deferred revenue and will be recognized as revenue in subsequent years following the completion of the ELATIVE double-blind study. Top-line results from that Phase 3 study evaluating Elafibranor to treat PBC should be out in the second quarter of next year. April Company Presentation The company is also working on a simple non-invasive test with Labcorp to identify at risk patients for NASH. This will be important if/when a drug is eventually approved for NASH. The company already has a significant database of patients from the work it did with its own NASH development which ended with the failure of the RESOLVE-IT trial in 2020. More data will be added with Ipsen's work on PBC. April Company Presentation The company is also working with other NASH development trials to ensure they knew steroids in their clinical trials, so that they can generate data with it. They also would naturally allow clients to use this test built on Genfit's NIS4 technology out of five blood based biomarker panels called NASHNext. That will launch from Labcorp if it is eventually approved. Genfit has an exclusive license agreement with LabCorp around this test. Genfit hopes this becomes the standard to identify at-risk NASH patients, provided a drug or drugs is approved for this widespread affliction. April Company Presentation The company also has two Phase 1 studies evaluating a candidate called NTZ, which they identified through phenotypic screening. The first Phase 1 study is focused on hepatic impairment, results from that study should be out shortly. The other Phase 1 study is focused on renal impairment. Data for this trial expected to be available in the fourth quarter of 2022. April Company Presentation Finally, late last year Genfit licensed an investigational compound from Genoscience Pharma called GNS5611. Genfit hopes to launch a Phase 1b/2 study towards the end of this year to evaluate this candidate for treating Cholangiocarcinoma (Bile Duct Cancer) which could be eligible for Orphan Drug status. Study data from this trial should be out in the first half of 2024.

Analys av ersättningar till VD

Hur har M. Prigent:s ersättning förändrats jämfört med Genfit:s resultat?
DatumTotal ersättningLönFöretagets resultat
Jun 30 2025n/an/a

-€39m

Mar 31 2025n/an/a

-€19m

Dec 31 2024€682k€406k

€2m

Sep 30 2024n/an/a

€12m

Jun 30 2024n/an/a

€22m

Mar 31 2024n/an/a

-€3m

Dec 31 2023€664k€394k

-€29m

Sep 30 2023n/an/a

-€32m

Jun 30 2023n/an/a

-€34m

Mar 31 2023n/an/a

-€29m

Dec 31 2022€632k€375k

-€24m

Sep 30 2022n/an/a

€12m

Jun 30 2022n/an/a

€48m

Mar 31 2022n/an/a

€58m

Dec 31 2021€562k€325k

€67m

Sep 30 2021n/an/a

€14m

Jun 30 2021n/an/a

-€39m

Mar 31 2021n/an/a

-€70m

Dec 31 2020€455k€325k

-€101m

Sep 30 2020n/an/a

-€84m

Jun 30 2020n/an/a

-€67m

Mar 31 2020n/an/a

-€66m

Dec 31 2019€325k€95k

-€65m

Ersättning vs marknad: M. s total kompensation ($USD 792.04K ) är under genomsnittet för företag av liknande storlek på US marknaden ($USD 2.45M ).

Ersättning vs inkomst: Ersättningen för M. har ökat samtidigt som företaget är olönsamt.

VD OCH KONCERNCHEF

M. Prigent (57 yo)

6.5yrs
Anställning
€681,945
Kompensation

Mr. M. Pascal Prigent has been Chief Executive Officer of Genfit SA since September 16, 2019. He served as Executive Vice President of Marketing & Commercial Development at Genfit SA since May 31, 2018 unt...

Ledningsgrupp

NamnPositionAnställningKompensationÄgarskap
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
M. Prigent
Chief Executive Officer6.5yrs€681.95k0.062%
$ 333.8k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
Thomas Baetz
Chief Financial Officer4.9yrsinga uppgifteringa uppgifter
Pascal Caisey
Chief Operating Officer4yrsinga uppgifter0.0030%
$ 16.3k
Sakina Sayah-Jeanne
Chief Scientific Officerless than a yearinga uppgifteringa uppgifter
Jean-Christophe Marcoux
Chief Corporate Affairs Officer3yrsinga uppgifter0.0094%
$ 50.8k
Laurent Lannoo
Corporate Secretary & Director of Legal Affairs18.2yrsinga uppgifter0.023%
$ 122.1k
Stefanie Magner
Chief Compliance Officer & Executive VP of International Legal Affairs5yrsinga uppgifter0.0055%
$ 30.0k
Emilie Desodt
Executive Vice President of Human Resources4yrsinga uppgifter0.00047%
$ 2.5k
John Brozek
Executive Vice President of Data & Information Technology3yrsinga uppgifter0.0060%
$ 32.7k
Tom Huijbers
Executive Vice President of Regulatory3yrsinga uppgifteringa uppgifter
4.0yrs
Genomsnittlig anställningstid
53yo
Genomsnittlig ålder

Erfaren ledning: GNFT.Y s ledningsgrupp anses vara erfaren ( 4 års genomsnittlig anställningstid).

Styrelseledamöter

NamnPositionAnställningKompensationÄgarskap
Jean-Francois Mouney
Co-Founder & Chairman of the Board8.8yrs€382.68k0.094%
$ 506.5k
Bart Staels
Co-Founder & Chairman of the Scientific Advisory Boardno datainga uppgifteringa uppgifter
Philippe Moons
Board Observer5.1yrs€14.17k0.0021%
$ 11.3k
Florence Séjourné
Director8.8yrsinga uppgifteringa uppgifter
Scott L. Friedman
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Arun Sanyal
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Michael Trauner
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Catherine Larue
Independent Director8.8yrs€50.14kinga uppgifter
Vlad Ratziu
Member of Scientific Advisory Boardno datainga uppgifteringa uppgifter
Anne-Helene Monsellato
Independent Director8.8yrs€45.78kinga uppgifter
Katherine Kalin
Independent Director5.7yrs€38.39k0.010%
$ 54.3k
Eric Baclet
Independent Vice-Chairman of the Board5.7yrs€68.42k0.0024%
$ 13.0k
8.8yrs
Genomsnittlig anställningstid
63yo
Genomsnittlig ålder

Erfaren styrelse: GNFT.Y s styrelse anses vara erfaren ( 8.8 års genomsnittlig mandatperiod).

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/03/11 10:33
Aktiekurs vid dagens slut2026/03/09 00:00
Intäkter2025/06/30
Årlig intjäning2024/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Genfit S.A. bevakas av 14 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Geoffrey MeachamBofA Global Research
Arnaud CadartCIC Market Solutions (ESN)
Alethia YoungDeutsche Bank